pills-istock-525984851
sprng23 / iStockphoto.com
23 March 2017Americas

PTAB upholds Biogen’s MS drug patent

A Biogen patent covering the drug Tecfidera (dimethyl fumarate) has been  upheld by the Patent Trial and Appeal Board (PTAB), after a challenge from Kyle Bass’s Coalition for Affordable Drugs.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
21 September 2020   In a blow for biotechnology company, Biogen, a US federal judge has ruled that its lone surviving patent on multiple-sclerosis drug Tecfidera should remain invalid because the matter had already been resolved by another court.

More on this story

Biotechnology
21 September 2020   In a blow for biotechnology company, Biogen, a US federal judge has ruled that its lone surviving patent on multiple-sclerosis drug Tecfidera should remain invalid because the matter had already been resolved by another court.

More on this story

Biotechnology
21 September 2020   In a blow for biotechnology company, Biogen, a US federal judge has ruled that its lone surviving patent on multiple-sclerosis drug Tecfidera should remain invalid because the matter had already been resolved by another court.